Shots:
- The US FDA approved Myqorzo (aficamten) is now commercially available in the US for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms
- Myqorzo is a QD, oral cardiac myosin inhibitor available in 5, 10, 15, and 20 mg tablets and directly targets hypercontractility and LVOT obstruction associated with oHCM
- The approval was based on the pivotal P-III (SEQUOIA-HCM) study, published in The NEJM; Myqorzo is available only through a REMS program due to the risk of heart failure related to systolic dysfunction
Ref: Cytokinetics | Image: Cytokinetics | Press Release
Related News: Cytokinetics Reports the US FDA Approval of Myqorzo (Aficamten) for Obstructive Hypertrophic Cardiomyopathy (oHCM)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
